Pathophysiology of iron metabolism: Diagnostic and therapeutic implications;Fisiopatología del metabolismo del hierro: Implicaciones diagnósticas y terapéuticas

Nefrologia

Volumn 25, Issue 1, 2005, Pages 9-19

  Munoz Gomez M ^a   Campos Garriguez A ^b   Garcia Erce J A ^c   Ramirez Ramirez G ^b  

^a GIEMSA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

CHRONIC KIDNEY FAILURE; HUMAN; INTESTINE; IRON DEFICIENCY ANEMIA; IRON METABOLISM DISORDER; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANEMIA, IRON-DEFICIENCY; HUMANS; INTESTINES; IRON; IRON METABOLISM DISORDERS; KIDNEY FAILURE, CHRONIC;

EID: 20544454877     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. th ed. New York: MacGraw-Hill, p. 399-405, 2001.
2. Toto RD: Anemia of the chronic disease: Past, present, and future. Kidney Int 64 (Supl. 87): S20-S23, 2003.
3. Giménez LF, Scheel PJ: Clinical application of recombinant erythropoietin in renal dialysis patients. Hematol Oncol Clin North Am 8: 913-26, 1994.
4. Geerlings W, Morris RW, Brunner FP, Brynger H, Ehrich JH, Fassbinder W y cols.: Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA Registry. Nephrol Dial Transplant 8: 585-9, 1993.
5. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Section II. Target for anaemia treatment. Nephrol Dial Transplant 19 (Supl. 2): ii6-ii15, 2004.
6. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay, Mittman N: Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. 64 (Supl. 87): S6-S11, 2003.
7. Krantz SB: Erythropoietin. Blood 77: 419-434, 1991.
8. Valderrábano F: Anemia management in chronic kidney disease patients: An overview of current clinical practice. Nephrol Dial Transplant 17 (Supl. 1): 13-18, 2002.
9. Cases A, Reverter JC, Escolar G, Sorribes J, López Pedret J, Revert L y cols.: Efecto del tratamiento con eritropoyetina recombinante humana sobre la coagulación y la fibrinolisis. Nefrología 14: 87-91, 1994.
10. Martín Rivas J, Pérez García A, Moll R, Cerveró A: Acción directa de la eritropoyetina humana recombinante (r-HuEPO) sobre el funcionalismo plaquetar en pacientes urémicos en hemodiálisis. Nefrología 16: 46-53, 1996.
11. Díez JJ, Iglesias P: Acciones de la eritropoyetina recombinante humana sobre la secreción hormonal hipofisaria en pacientes urémicos. Nefrología 13: 280-90, 1993.
12. Solis C, Miguel JL, Fernández MJ, Quevedo E, Borrego F, Martínez Ara J: Acción de la rHuEPO sobre la hemorreología de los pacientes en hemodiálisis crónica. Nefrología 12 (Supl. 1): 47-52, 1992.
13. Van Damme-Lombaerts R, Herman J: Erythropoietin treatment in children with renal failure. Pediatr Nephrol 13: 148-52, 1999.
14. Painter P, Moore GE: The impact of recombinant human erythropoietin on exercise capacity in hemodialysis patients. Adv Ren Replace Ther 1: 55-65, 1994.
15. Leanza H, Giacoletto S, Najun C, Barreneche M: Niveles de hemoglobina y probabilidad de mejor calidad de vida en hemodializados crónicos. Nefrología 20: 440-4, 2000.
16. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM y cols.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-5900, 1998.
17. Gómez Fernández P, Almaraz M, Ramos M, Pérez Mijares R, Castro A, Vargas Machuca JC: Presión arterial, eritropoyetina y función del sistema nervioso autónomo. Nefrología 13: 291-298, 1993.
18. Fernández-Gallego J, Ramos B, Ruiz A, Contreras J, Álvarez Bustos G, López de Novales E: Estudio de algunos factores que pueden influir en el tratamiento con eritropoyetina de la anemia en hemodiálisis. Nefrología 20: 164-70, 2000.
19. Fernández-Reyes MJ, Álvarez-Ude F, Sánchez R, Mon C, Iglesias P, Vázquez A: Estado nutricional, comorbilidad e inflamación en hemodiálisis. Nefrología 20: 540-9, 2000.
20. Nisseson AR, Carytan C: Controversies in iron management. Kidney Int 64 (Supl. 87): S64-S71, 2003.
21. Ramírez G, Moreno MJ, Pérez I: Eritropoyesis, hierro y eritropoyetina. En Muñoz M (coord.) Anemia y Transfusión en Cirugía. Málaga: SPICUM 33-17, 2002.
22. Remacha A: Hematínicos y factores de crecimiento hematopoyético. En Muñoz M (coord.) Actualización en Medicina Transfusional Perioperatoria. Málaga: SPICUM 61-68, 2004.
23. Andrews NC: Disorders of iron metabolism. N Engl J Med 341: 1986-95, 1999.
24. Riedel HD, Remus AJ, Fitsher BA, Stremmel W: Characterization and partial purification of a ferrireductase from human duodenal microvillous membranes. Biochem J 309: 745-748, 1995.
25. Gushin H, MacKenzie B, Berger UV y cols.: Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388: 482-188, 1997.
26. Remacha AF: El metabolismo del hierro (FE): nuevos aspectos metabólicos y fisiopatológicos. En: García Conde J (ed.) Hematología, citocinas, inmunoterapia y terapia celular. Madrid: Aran 189-203, 2001.
27. Conrad ME, Umbreit JN: Iron absorption and transport - An update. Am J Hematol 64: 287-98, 2000.
28. Simovich MJ, Conrad ME, Umbreit JN, Moore EG, Hainsworth LN, Smith HK: Cellular location of proteins related to iron absorption and transport. Am J Hematol 69: 164-70, 2002.
29. McKie AT, Wehr K, Simpson RI, Peters TJ, Hentze MW, Farzaneh E: Molecular cloning and characterization of a novel duodena I-specific gene implicate in iron absorption. Biochem Soc Trans 26:S264, 1998.
30. Vulpe CD, Kuo YM, Murphy TL y cols.: Hephastin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Gent 21: 195-199, 1999.
31. Santos M. de Sousa M, Marx JJM: Regulation of intracelular iron levels in iron-aceptor and iron-donor cells. Transfus Sci 23: 225-35, 2000.
32. a ed. Barcelona: Harcourt 105-30, 2001.
33. Finch C: Regulators of iron balance in humans. Blood 84: 1697-1702, 1994.
34. Frazer DM, Anderson GJ: The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cell Mol Dis 30:288-97, 2003.
35. Yamaji S, Sharp P, Ramesh B, Srai SK: Inhibition of iron transport across human intestinal epithelial cells by hepcidin. Blood 104: 2178-80, 2004.
36. Anderson GJ, Frazer DM, Wilkins SJ, Becker EM, Millard KN, Murphy TL y cols.: Relationships between intestinal iron-transporter expression, hepatic hepcidin levels and the control of iron absorption. Biochem Soc Trans 30: 724-6, 2002.
37. Frazer DM, Inglis HR, Wilkins SJ, Millard KN, Steele TM, McLaren GD: Delayed hepcidin response explains the lag period in iron absorpion following a stimulus to increase erythropoiesis. Gut 53: 1509-15, 2004.
38. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I y cols.: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110: 1037-14, 2002.
39. Sposi N, Cianetti L, Tritarelli E, Pelosi E, Militi S, Barberi T y cols.: Mechanims of differential transferrin receptor expresion in normal hematopoiesis. Eur J Biochem 6762-74, 2000.
40. Weiss G, Houston T, Kastner S, Jöher K, Grünrwald K, Brock JH: Regulation of cellular iron metabolism by erythropoietin: activation of iro-regulatory protein and up regulation of transferring receptor expression in erythroid cells. Blood 89: 680-7, 1997.
41. Tuomainen TP, Punnonen K, Nyyssönen K, Salonen JT: Association between bodu iron stores and the risk of acute myocardial infraction in men. Circulation 97: 1461-6, 1998.
42. Roest M, Van der Schouw YT, De Valk B, Marx JJM, Tempelman MJ, De Groot PG y cols.: Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 100: 1268-73, 1999.
43. Imlay JA, Chin SM, Linn S: Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro. Science 240: 640-2, 1988.
44. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, in a type II acute-phase protein. Blood 101: 2462-3, 2003.
45. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK y cols.: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1272-6, 2004.
46. Piñero DJ, Hu J, Cook BM, Scaduto Jr, RC, Connor JR: Interleukin-1b increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool. Biochim Biophys Acta 1497: 279-88, 2000.
47. Graziadei I, Weiss G, Egger C, Niederwieser D, Patsch JR, Vogel W: Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein alpha1-antitrypsin. Exp Hematol 26:1053-60, 1988.
48. Vanholder R, Van Bieson W, Ringoir S: Contributing factors to the inhibition of phagocytosis in haemodialysed patients. Kidney Int 44: 208-14, 1993.
49. Brock JH, De Sou sa M: Immunoregulating by iron-binding proteins. Immunol Today 7: 30-1, 1986.
50. Vychytil A, Haag-Weber M: Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int. 55 (Supl.): S71-8, 1999.
51. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W y cols.: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623-32, 2004.
52. Oppenheimer SJ: Iron and its relation to immunity and infectious disease. J Nutr 131: 616S-635S, 2001.
53. Scrimshaw NS, Sangiovanni JP: Synergism of nutrition, infection, and immunity: an overview. Am J Clin Nutr 66: 464S-477S, 1997.
54. Harju E: Empty iron stores as a significant risk factor in abdominal surgery. J Parent Enteral Nutr 12: 282-5, 1988.
55. Bellamy MC, Gednaey JA: Unrecognised iron deficiency in critical illness. Lancet 352: 1903, 1998.
56. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, Van de Wiel A: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 28: 2773-8, 2000.
57. Biesma DH, Van de Wiel A, Beguin Y, Keraaijenhagen RJ, Marx JJM: Post-operative erythropoiesis is limited by the inflammatory effect of surgery on iron metabolism. Eur J Clin Invest 25: 383-9, 1995.
58. Van Iperen CE, Kraaijenhagen RJ, Biesma DH, Beguin Y, Marx JJM, Van de Wiel A: Iron metabolism and erythropoiesis after surgery. Br J Surg 85: 41-5, 1998.
59. Thomas C, Thomas L: Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48: 1066-76, 2002.
60. Muñoz JA, Fernández Valle MC, Risueño CE, Ladines R, Chozas N, de Cos C: Papel del receptor de la transferrina en el diagnóstico de las anemias ferropénicas y asociadas a procesos respiratorios inflamatorios. Haematologica (ed. esp.) 78 (Supl. 1): 325-329, 2002.
61. Roque ME, Sandoval MJ, Aggio MC: Serum erythropoietin and its relation with soluble transferrin receptor in patients with different types of anaemia in a lilaclly defined reference population. Clin Lab Haem 23: 291-5, 2001.
62. Cazzola M, Ponchio L, De Benedetti F, Ravelli A, Rosti V, Beguin Y y cols.: Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87: 4824-30, 1996.
63. Fishbane S, Kowalski EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 13: 381-4, 2000.
64. MacDougall IC: Intravenous administration of iron in epoetin-treated haemodialysis patients-which drugs, which regimen? Nephrol Dial Transplant 15: 1743-5, 2000.
65. Besahra S, Lundqvist H, Sundin J, Tolmachev V, Valind S, Antoni G y cols.: Kinetic analysis of 52Fe-labelled iron(III)-hydroxide sucrose complex following bolus administration using positron emission tomography. Br J Haematol 104: 288-295, 1999.
66. Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J y cols.: Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int. 66: 1193-8, 2004.